Impact of Inpatient Initiation of Sodium-Glucose Cotransporter-2 Inhibitors on Prescription Rates in Patients With Heart Failure With Reduced Ejection Fraction.
住院患者開始使用鈉葡萄糖共轉運子-2抑制劑對心衰患者降低射血分數處方率的影響。
Am J Cardiol 2023-10-12
The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials.
SGLT-2抑制劑在心力衰竭管理中的角色:心力衰竭試驗中臨床結果終點的持續挑戰。
Pharmaceutics 2023-11-02
The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
SGLT2 抑制劑對心臟收縮功能保留型心衰患者心血管結果的影響。
Ann Pharmacother 2024-04-12
Temporal Trends in Heart Failure Management and Outcomes: Insights From a Japanese Multicenter Registry of Tertiary Care Centers.
心衰管理與結果的時間趨勢:從日本三級保健中心的多中心登記中獲得的見解。
J Am Heart Assoc 2023-12-20
Success in Heart Failure? An Investigation of Heart Failure Readmission Rates and Medication Regimen Optimization.
心臟衰竭的成功?心臟衰竭再入院率及藥物療程優化的研究。
Sr Care Pharm 2024-03-01
A real-world experience of a prescribing policy for SGLT2-inhibitors in HFrEF in a Malaysian public tertiary cardiac centre.
馬來西亞公立三級心臟中心對於SGLT2抑制劑在HFrEF治療中的處方政策的實際經驗。
Med J Malaysia 2024-04-01
Heart Failure with Mid-Range or Mildly Reduced Ejection Fraction in the Era of Sodium-Glucose Co-Transporter 2 Inhibitors: Do We Now Provide Better Care for the "Middle Child of HF"? Real-World Experience from a Single Clinical Centre.
SGLT-2 抑制劑時代中等範圍或輕度降低射血分數的心臟衰竭:我們現在是否為「HF 中間兒童」提供更好的照護?單一臨床中心的實際經驗。
J Cardiovasc Dev Dis 2024-06-26
Inpatient Use of Guideline-Directed Medical Therapy During Heart Failure Hospitalizations Among Community-Based Health Systems.
社區醫療系統中心臟衰竭住院期間指導性醫療療法的住院使用情況。
JACC Heart Fail 2024-09-13